1  total severity score (primary endpoint) and Sheehan Disability Scale (SDS) functional impairment sco

2 36, Quality of Life in Depression Scale, and Sheehan Disability Scale.

3 pressive Symptomology Self-Report score, and Sheehan Disability Scale score.

4 bthreshold symptoms had significantly higher Sheehan Disability Scale scores (greater impairment) tha

5      Other secondary outcomes were change in Sheehan Disability Scale score from baseline to day 43 a

6 Role impairment was assessed with a modified Sheehan Disability Scale.

7 s also associated with significantly reduced Sheehan Disability Scale scores compared with niacin (me

8 nt improvements in scores on the NIMH scale, Sheehan Disability Scale, and Clinical Global Impression

9 em Hamilton Depression Rating Scale, and the Sheehan Disability Scale.

10 tly increased disability, as measured by the Sheehan Disability Scale.

11                 For all three domains of the Sheehan Disability Scale, significantly greater improvem

12 ificantly less SCI-related disability on the Sheehan Disability Scale at 12 weeks compared with place

13 nctional disability, including scores on the Sheehan Disability Scale, were collected at the time of

14 nctional impairment, including scores on the Sheehan Disability Scale, were collected at the time of

15  Disorders, a drug use disorders screen, the Sheehan Disability Scale, and a questionnaire that probe

16 , and MDD disability as quantified using the Sheehan Disability Scale and the World Health Organizati

17 ial life, and home/family life) by using the Sheehan Disability Scale.

18 and functional impairment, measured with the Sheehan Disability Scale (SDS, the secondary endpoint) w

19      Disorder severity was measured with the Sheehan Disability Scale.

20 to mental health symptoms, measured with the Sheehan Disability Scale.

21  functional impairment was measured with the Sheehan Disability Scale.